CGTLive’s Weekly Rewind – April 15, 2022

Article

Review top news and interview highlights from the week ending April 15, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. GD2-CAR T-Cell Therapy Yields Clinical Benefit in Glioma

While the lower IV dose was generally well-tolerated, the higher dose yielded cases of serious cytokine release syndrome.

2. Liso-Cel Approved for R/R B-Cell Lymphoma by European Commission

The decision was based on findings from the phase 1 TRANSCEND NHL 001 clinical trial.

3. Combination CAR T-Cell Therapy, RNA Vaccine Shows Efficacy in Solid Tumors

The novel regimen from BioNTech demonstrated encouraging results in patients with testicular or ovarian cancer.

4. Cord Blood Combined Natural Killer Cell Engager Therapy Shows Efficacy in Lymphoma

AFM13 is currently also being evaluated on its own in lymphoma in a phase 2 registrational study.

5. FBX-101 and the RESKUE Trial: Exploring AAV-Based Gene Therapies for Krabbe Disease

Erandi De Silva, PhD, co-founder and senior vice president of product development at Forge Biologics, discusses the dual approach of her company in manufacturing and also developing adeno-associated viral-based gene therapies, including FBX-101 for Krabbe disease.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Related Content
© 2025 MJH Life Sciences

All rights reserved.